Back to News
Market Impact: 0.25
Akebia Therapeutics, Inc. Receives Nasdaq Minimum Bid Price Deficiency Notice
Source: Nasdaq
Regulation & LegislationCompany Fundamentals
Akebia Therapeutics received a Nasdaq Listing Qualifications Department deficiency letter on October 21, 2026, after its common stock's bid price failed to meet the applicable requirement for 30 consecutive business days. The supplied article text is cut off before stating the bid-price threshold or any compliance deadline or company response.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
AKBA-0.75
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- The $4.7 Trillion Bet: When Does AI Capex Become AI Revenue?
- Equity Research Automation Statistics: A 2026 Evidence Check